Based on these studies, it has been hypothesized that Erk1/2 could be an important target for glaucoma therapeutics.[46] In the current study, eyes treated with the Erk1/2 pathway blocker U0126 inhibited IOP reduction following KATP channel opening with DZ and NCD, suggesting that downstream effects of these compounds are directly mediated through the Erk1/2 signaling pathway. Here, MAPK3 is linked to glaucoma.